DDInter1910 DDInter1763
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Valdecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dextromethorphan
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Valdecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Enoxaparin {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Valdecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Valdecoxib may cause a minor interaction that can limit clinical effects when taken with Dextromethorphan and Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Temsirolimus (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Temsirolimus (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is upregulated by Temsirolimus (Compound)